钙黏素和整合素在卵巢上皮性癌中的研究进展

doi:10.11904/j.issn.1002-3070.2017.06.013

摘要/Abstract

摘要： 卵巢上皮性癌(EOC)是妇科癌症中最致命的恶性肿瘤。在过去的30年间,虽然诊断和治疗水平取得了进展,但是卵巢上皮性癌的发病率和死亡率却保持不变。卵巢上皮性癌腹膜转移癌晚期发病于附着的小簇癌细胞,这些癌细胞从初始部位脱落并经由腹水携带附着于腹部腹膜或网膜。这种行为表明细胞-细胞或细胞-基质黏附机制调节卵巢上皮性癌的生长和增殖。复杂的下游信号可能受黏附分子和共表达激活的信号蛋白之间的功能性串扰所影响,导致卵巢上皮性癌细胞的增殖/存活和迁移/侵袭。本文旨在阐述细胞与细胞机制的影响,该过程由钙黏素和细胞-细胞外基质黏附,由整合素对膜受体和细胞质蛋白质介导的信号级联放大,这些在卵巢上皮性癌细胞的增殖、迁移和侵袭中起着一定的作用。

关键词: 卵巢上皮性癌, 钙黏素, 整合素, 信号转导

Abstract: Epithelial ovarian cancer(EOC)is the most deadly malignant tumor in gynecological cancer.In the past 30 years,although the levels of diagnosis and treatment have made progress,the incidence of EOC and mortality are constant.Over the past few decades,a comprehensive study for molecular mechanisms of EOC progression has been conducted in order to develop new and more effective treatments.Advanced peritoneal metastases occur in the attached small clusters of cancer cells,which shed from the initial site and carried it through the ascites to the abdominal peritoneum or omentum.This behavior suggests that cell-cell or cell-matrix adhesion mechanisms regulate the growth and dissemination of EOC.Complex downstream signaling may be affected by functional crosstalk between adhesion molecules and,co-expressed and activated signaling proteins,which affect the proliferation/survival and migration/invasion of EOC cells.The aim of this review is to define effects of cell and cellular mechanisms,which are adhered by the cadherin and the cell-extracellular matrix,and cascaded by integrin-mediated membrane receptor and cytoplasmic protein-mediated cascade amplification,which is expressed in proliferation,migration and invasion of epithelial ovarian cancer cells.

Key words: Epithelial ovarian cancer, Cadherins, Integrin, Signal transduction

中图分类号:

R737.31

刘心, 徐颖娟, 杨畅, 娄阁审校. 钙黏素和整合素在卵巢上皮性癌中的研究进展[J]. 实用肿瘤学杂志, 2017, 31(6): 548-553.

LIU Xin, XU Yingjuan, YANG Chang, LOU Ge. Research progress on cadherins and integrins in ovarian epithelial cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 548-553.

参考文献

1 Kipps E,Tan DS,Kaye SB.Meeting the challenge of ascites in ovarian cancer:New avenues for therapy and research[J].Nat Rev Cancer,2013,13(4):273-282.
2 Ahmed N,Stenvers KL.Getting to know ovarian cancer ascites:Opportunities for targeted therapy-based translational research[J].Front Oncol,2013,25(3):256.
3 Takeichi M.Dynamic contacts:Rearranging adherens junctions to drive epithelial remodeling[J].Nat Rev Mol Cell Biol,2014,15(6):397-410.
4 Miow QH,Tan TZ,Ye J,et al.Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer[J].Oncogene,2015,34(15):1899-1907.
5 Reddy P,Liu,L,Ren,C,et al.Formation of E-cadherin-mediated cell-cell adhesion activates AKT and mitogen activated protein kinase via phosphatidylinositol 3 kinase and ligand-independent activation of epidermal growth factor receptor in ovarian cancer cells[J].Endocrinol,2005,19(10):2564-2578.
6 Dong LL,Liu L,Ma CH,et al.E-cadherin promotes proliferation of human ovarian cancer cells in vitro via activating MEK/ERK pathway[J].Acta Pharmacol Sin,2012,33(6):817-822.
7 Cheung LW,Leung PC,Wong AS.Cadherin switching and activation of p120 catenin signaling are mediators of gonadotropin-releasing hormone to promote tumor cell migration and invasion in ovarian cancer[J].Oncogene,2010,29(16):2427-2440.
8 Cheung LW,Mak AS,Cheung AN,et al.P-cadherin cooperates with insulin-like growth factor-1 receptor to promote metastatic signaling of gonadotropin-releasing hormone in ovarian cancer via p120 catenin[J].Oncogene,2011,30(26):2964-2974.
9 Cheung LW,Yung S,Chan TM,et al.Targeting gonadotropin-releasing hormone receptor inhibits the early step of ovarian cancer metastasis by modulating tumor-mesothelial adhesion[J].Mol Ther,2013,21(1):78-90.
10 Ip CK,Yung S,Chan TM,et al.p70S6 kinase drives ovarian cancer metastasis through multicellular spheroid-peritoneum interaction and P-cadherin/β1 integrin signaling activation[J].Oncotarget,2014,5(19):9133-9149.
11 Barczyk M,Carracedo S,Gullberg D.Integrins[J].Cell Tissue Res,2010,339(1):269-280.
12 Zhao X,Guan JL.Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis[J]Adv Drug Deliv Rev,2011,63(8):610-615.
13 Yousif NG.Fibronectin promotes migration and invasion of ovarian cancer cells through up-regulation ofFAK-PI3K/Akt pathway[J].Cell Biol Int,2014,38(1):85-91.
14 Desgrosellier JS,Cheresh DA.Integrins in cancer:Biological implications and therapeutic opportunities[J].Nat Rav Cancer,2010,10(1):9-22.
15 Ivaska J,Heino J.Cooperation between integrins and growth factor receptors in signaling and endocytosis[J].Annu Rev Cell Dev Biol,2011,27:291-320.
16 Jiao Y,Ou W,Meng F,et al.Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation[J].Mol Cancer,2011,10:125.
17 Alper O,Bergmann-Leitner ES,Bennett TA,et al.Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells[J].J Natl Cancer Inst,2001,93(18):1375-1384.
18 Sawada K,Radjabi AR,Shinomiya N,et al.c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination andinvasion[J].Cancer Res,2007,67(4):1670-1679.
19 Mitra AK,Sawada K,Tiwari P,et al.Ligand-independent activation of c-Met by fibronectin and α5β1-integrin regulates ovarian cancer invasion and metastasis[J].Oncogene,2011,30(13):1566-1576.
20 Kwon Y,Smith BD,Zhou Y,et al.Effective inhibition of c-MET-mediated signaling,growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment[J].Oncogene,2015,34(2):144-153.
21 Moran-Jones K,Brown LM,Samimi G.INC280,an orally available small molecule inhibitor of c-MET,reduces migration and adhesion in ovarian cancer cell models[J].Sci Rep,2015,5:11749.
22 Mu J,Abe Y,Tsutsui T,et al.Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity[J].Jpn J Cancer Res,1996,87(9):963-971.
23 Brown M,Black JR,Sharma R,et al.Gene of the month:Axl[J].J Clin Pathol,2016,69(5):391-397.
24 Zhang Z,Lee JC,Lin L,et al.Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer[J].Nat Genet,2012,44(8):852-860.
25 Rankin EB,Fuh KC,Taylor TE,et al.Axl is an essential factor and therapeutic target for metastatic ovarian cancer[J].Cancer Res,2010,70(19):7570-7579.
26 Rea K,Pinciroli P,Sensi M,et al.Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome[J].Oncotarget,2015,6(31):30859-30875.
27 Lualdi M,Pedrini E,Rea K,et al.Pleiotropic modes of action in tumor cells of RNASET2,an evolutionary highly conserved extracellular RNase[J].Oncotarget,2015,6(10):7851-7865.
28 Yin F,Liu L,Liu X,et al.Downregulation of tumor suppressor gene ribonuclease T2 and gametogenetin binding protein 2 is associated with drug resistance in ovarian cancer[J].Oncol Rep,2014,32(1):362-372.

[1]	赵相轩, 温锋, 毛晓楠综述, 卢再鸣审校. 细胞凋亡在原发性肝癌治疗中的作用研究进展[J]. 实用肿瘤学杂志, 2016, 30(5): 448-452.
[2]	周虹, 陈莉. TLR3对NF-κB信号通路的调控在肿瘤中的意义[J]. 实用肿瘤学杂志, 2015, 29(6): 540-544.
[3]	刘本鲲综述, 徐世东, 孙大为审校. TGF-β在肿瘤微环境中多重作用的研究进展[J]. 实用肿瘤学杂志, 2015, 29(5): 454-457.
[4]	毛银玲,曹宇星,项亚光,娄长杰,李志伟,张艳桥. II期结肠腺癌组织P-STAT5蛋白表达及其临床意义[J]. 实用肿瘤学杂志, 2013, 27(3): 251-255.
[5]	童英, 刘露, 李春东, 任东平. ILK及E-钙黏蛋白的表达在宫颈鳞癌发病中的意义[J]. 实用肿瘤学杂志, 2011, 25(5): 431-436.
[6]	赵锐, 孔祥波, 金宁, 张刚. siRNA干扰cytohesins导致前列腺癌细胞中IGFR信号减低[J]. 实用肿瘤学杂志, 2011, 25(4): 361-364.
[7]	顾海涛, 石欣, 林士波, 张翼, 杨军, 钱程佳. PTEN、PIK3CA在培美曲塞耐药的胰腺癌细胞株Patu8988中的表达及其意义的初步探讨[J]. 实用肿瘤学杂志, 2010, 24(2): 112-116.
[8]	杨姗姗, 李佩玲, 孟春艳. Cyr61在卵巢上皮性癌中的表达及其与血管生成关系的研究[J]. 实用肿瘤学杂志, 2010, 24(1): 24-28.
[9]	徐冶, 高颖, 娄阁. 力朴素与奈达伯联合先期化疗对晚期卵巢上皮性癌的临床观察^△[J]. 实用肿瘤学杂志, 2008, 22(6): 512-513.
[10]	陈慧娟;欧希龙. 整合素β1与胃癌转移的研究进展[J]. 实用肿瘤学杂志, 2008, 22(02): 195-197.